Qiagen N.V. (0RLT.IL)
| Previous close | 43.54 |
| Open | 0.00 |
| Bid | 40.34 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 225,650 |
| Market cap | 9.882B |
| Beta (5Y monthly) | 0.39 |
| PE ratio (TTM) | 29.73 |
| EPS (TTM) | 1.35 |
| Earnings date | 30 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireQIAGEN enhances bioinformatics workflows with new secondary analysis solution for oncology and inherited disease applications
QCI Secondary Analysis a cloud-based software directly integrated with QCI Interpret, enabling high-throughput secondary analysis of clinical next-generation sequencing data // New software advances precision medicine by enabling smaller and decentralized labs to adopt NGS testing with efficiency, consistency and confidence // Combination of QCI Secondary Analysis and QCI Interpret provide a secure and compliant environment for trusted and scalable bioinformatics workflows for oncology and inher
Simply Wall St.Qiagen N.V. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next
It's been a good week for Qiagen N.V. ( NYSE:QGEN ) shareholders, because the company has just released its latest...
Insider MonkeyQiagen N.V. (NYSE:QGEN) Q1 2024 Earnings Call Transcript
Qiagen N.V. (NYSE:QGEN) Q1 2024 Earnings Call Transcript April 30, 2024 Qiagen N.V. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, thank you for standing by. I’m Melinda, your PGI call operator. Welcome, and thank you for […]
